SCA – Talk Bio

Actionable Insights Powered by AI

Biohaven Revives Troriluzole Hopes with Positive Update for Spinocerebellar Ataxia

7 months ago talkbio0Tagged Ataxia, Spinocerebellar, Clinical Trials, Infrequent, Neurodegenerative Disorders, New Drug Application, SCA, Troriluzole, United States Food and Drug Administration

Troriluzole, Spinocerebellar Ataxia (SCA), Biohaven Pharmaceuticals, Neurodegenerative Disorders, FDA New Drug Application (NDA), Clinical Trials, Rare Diseases